Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

Boehringer Ingelheim RSS Channel

Display # 
Title Published Date
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) 26 November 2015
Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years 12 November 2015
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research 11 November 2015
Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD 22 September 2015
International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes 17 September 2015
Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity 14 August 2015
Patients reporting better quality of communication by their physician show improved self-care 08 June 2015
Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment 26 May 2015
Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate 19 May 2015
Boehringer Ingelheim positioned for future growth with product launches 28 April 2015
New international survey of lung cancer oncologists highlights underutilization of personalized treatments 20 April 2015
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin 20 November 2014
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy 24 September 2014
Boehringer Ingelheim Statement on Hepatitis C drug development 29 June 2014
Boehringer Ingelheim will make detailed clinical trial data available to the scientific community 14 May 2014
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation 06 March 2014
Boehringer Ingelheim receives East Bay Innovation Award 19 February 2014
Crystal Bioscience and Boehringer Ingelheim announce multiple target antibody discovery collaboration 10 February 2014
New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin 04 December 2013
Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim 28 October 2013

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]